WCLC 2025 - Posters & ePosters-EP.08.45 Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced NSCLC and PD-L1 =50%: A Systematic Review and Meta-Analysis

EP.08.45 Real-World Long-Term Outcomes of First-Line Pembrolizumab in Advanced NSCLC and PD-L1 =50%: A Systematic Review and Meta-Analysis

Asset Subtitle

Guilherme Franceschini Machado

Meta Tag

Speaker Guilherme Franceschini Machado

Topic Local-Regional Non-small Cell Lung Cancer